Company / Capital Expenditures
Sarepta Therapeutics Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$102.0M
FY2025
5-year range
$38.5M / $137.0M
FY2021-FY2025
Trend
-25.5%
vs FY2024
Sector context
#21 of 194
Health Care
What the data says
Sarepta Therapeutics's capital expenditures of $102M is higher than 89% of companies in the Health Care sector (FY2025). Capital Expenditures has fluctuated over the past 10 years, ranging from $5M in FY2016 to $137M in FY2024.
Based on SEC 10-K filings.
$102M in FY2025 with a 5-year CAGR of +10.8%. Top quartile in the Health Care sector.
Improved from $76M to $102M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +7.4%
- 5-Year CAGR
- +10.8%
- 10-Year CAGR
- -
Sector benchmark
-13.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +10.8%, indicating consistent growth.
- In FY2025, capital expenditures decreased 25.5% year-over-year.
- Ranks #21 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $102.0M | -25.5% |
| FY2024 | $137.0M | +80.0% |
| FY2023 | $76.1M | -7.4% |
| FY2022 | $82.2M | +113.6% |
| FY2021 | $38.5M | -37.1% |
| FY2020 | $61.2M | +409.6% |
| FY2019 | $12.0M | -80.4% |
| FY2018 | $61.2M | +409.6% |
| FY2017 | $12.0M | +124.7% |
| FY2016 | $5.3M | +57.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026